Acrux Limited (ASX:ACR)

Market Cap	9.38M
Revenue (ttm)	802.00K
Net Income (ttm)	-5.99M
Shares Out	407.76M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	515,053
Average Volume	220,938
Open	0.0230
Previous Close	0.0230
Day's Range	0.0220 - 0.0230
52-Week Range	0.0220 - 0.0880
Beta	0.92
RSI	44.42
Earnings Date	May 26, 2025

About Acrux

Acrux Limited, together with its subsidiaries, engages in the development and commercialization of generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; Dapsone 5% and Dapsone 7.5% which are gels for the treatment of acne vulgaris; and Prilocaine 2.5% and Lidocaine 2.5%, a topical anaesthetic cream. It is also involved in the d...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 43
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACR

Financial Performance

In 2024, Acrux's revenue was 5.09 million, a decrease of -39.60% compared to the previous year's 8.43 million. Losses were -5.80 million, 659.2% more than in 2023.